About us Contacts Drug interactions: 390 212
Drug search by name

Lurasidone and Zykadia

Determining the interaction of Lurasidone and Zykadia and the possibility of their joint administration.

Check result:
Lurasidone <> Zykadia
Relevance: 23.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme. In a pharmacokinetic study, administration of a single 10 mg dose of lurasidone with the potent CYP450 3A4 inhibitor ketoconazole (400 mg/day for 5 days) resulted in a 6.9-fold increase in lurasidone peak plasma concentration (Cmax) and a 9-fold increase in systemic exposure (AUC) compared to administration alone. The AUC of lurasidone's active metabolite increased by 6-fold. MANAGEMENT: Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated. References "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA. Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Professional:

CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme. In a pharmacokinetic study, administration of a single 10 mg dose of lurasidone with the potent CYP450 3A4 inhibitor ketoconazole (400 mg/day for 5 days) resulted in a 6.9-fold increase in lurasidone peak plasma concentration (Cmax) and a 9-fold increase in systemic exposure (AUC) compared to administration alone. The AUC of lurasidone's active metabolite increased by 6-fold.

MANAGEMENT: Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated.

References
  • "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Lurasidone

Generic Name: lurasidone

Brand name: Latuda

Synonyms: n.a.

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction